8. Novartis AG (NYSE:NVS)
Novartis AG (NYSE: NVS) takes eighth place as a focused innovative-medicines company with important franchises in oncology, immunology, neuroscience and cardiovascular disease. The Swiss pharmaceutical giant has steadily moved away from being a sprawling healthcare conglomerate and is now concentrating on patented medicines with the potential to deliver higher margins and stronger long-term growth. Its priority brands include Kisqali for breast cancer, Kesimpta for multiple sclerosis, Scemblix for chronic myeloid leukemia, Pluvicto for prostate cancer and Leqvio for cholesterol management. This collection gives the company exposure to several of the pharmaceutical market’s most important therapeutic categories.
The second quarter of 2026 showed both the strength and weakness of the investment case. Net sales increased by only 1% at constant currencies, while core operating income remained flat. However, the company’s most important growth medicines continued expanding rapidly. Kisqali sales rose 43% at constant currencies, Kesimpta increased 32%, Scemblix climbed 89%, Pluvicto grew 43% and Leqvio advanced 59%. These are not small or experimental products buried inside an early-stage pipeline. They are commercial medicines already generating meaningful revenue and gaining market share. The challenge is that their growth must compensate for generic erosion affecting older products. During the first half of 2026, total net sales declined 2% at constant currencies and core operating income fell 7%.
The pipeline remains a major reason to keep Novartis AG (NYSE: NVS) among the best pharmaceutical stocks to watch. During the second quarter, the company advanced regulatory and clinical programs involving Rhapsido, Itvisma, Kisqali and experimental muscular-dystrophy treatments. Updated Kisqali data showed a clinically meaningful overall-survival benefit after six years in early breast cancer, while the company submitted del-zota for accelerated FDA approval in Duchenne muscular dystrophy. Still, management expects only low-single-digit sales growth for the full year, with core operating income projected to decline by a low-single-digit percentage. Novartis AG (NYSE: NVS) possesses several excellent medicines and an attractive long-term pipeline, but the near-term generic pressure prevents it from ranking alongside the faster-growing pharmaceutical companies higher on this list.
Click next to see the following stock...
